Premium
Host controls of HIV broadly neutralizing antibody development
Author(s) -
Kelsoe Garnett,
Haynes Barton F.
Publication year - 2017
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/imr.12508
Subject(s) - germinal center , immunology , biology , hiv vaccine , immune system , antibody , neutralizing antibody , b cell , virology , vaccine trial
Summary Induction of broadly neutralizing antibodies ( bNA bs) is a major goal of HIV vaccine development. BNA bs are made during HIV infection by a subset of individuals but currently cannot be induced in the setting of vaccination. Considerable progress has been made recently in understanding host immunologic controls of bNA b induction and maturation in the setting of HIV infection, and point to key roles for both central and peripheral immunologic tolerance mechanisms in limiting bnAb development. Immune tolerance checkpoint inhibition has been transformative in promotion of anti‐tumor CD 8 T‐cell responses in the treatment of certain malignancies. Here, we review the evidence for host controls of bNA b responses, and discuss strategies for the transient modulation of immune responses with vaccines toward the goal of enhancing germinal center B‐cell responses to favor bNA b B‐cell lineages and to foster their maturation to full neutralization potency.